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Abstract: Leber hereditary optic neuropathy (LHON) is one of the most common inherited 
optic neuropathies causing bilateral central vision loss. The disorder results from point muta-
tions in mitochondrial DNA and subsequent mitochondrial dysfunction. The primary cell type 
that is lost in LHON is the retinal ganglion cell, which is highly susceptible to disrupted ATP 
production and oxidative stress. Inheritance of LHON follows that of mitochondrial genetics, 
and it has a highly variable clinical phenotype, as other genetic and environmental factors also 
play a role. Although LHON usually presents with isolated vision loss, some patients suffer 
other neurological sequelae. For ill-defined reasons, male LHON mutation carriers are more 
affected than females. Most LHON patients remain legally blind, but a small proportion can 
experience spontaneous partial recovery, often within the first year of symptom onset. Unfor-
tunately, at this time there are no established curative interventions and treatment is largely 
supportive. Patients should be offered low vision services and counseled on mitigating risk 
factors for additional vision loss, such as smoking and consuming alcohol. Encouraging treat-
ments currently undergoing investigation includes ubiquinone analogs, such as idebenone, as 
well as gene therapy and stem cells to restore ATP synthesis and provide neuroprotection to 
surviving retinal ganglion cells.
Keywords: Leber hereditary optic neuropathy, mitochondria, neuro-ophthalmology, 
mitochondrial DNA
Introduction
Mitochondrial diseases were once thought of as rare disorders, in part due to failure 
to recognize the diagnosis because of the wide variability among phenotypes. They 
are increasingly recognized as a common cause of neurologic and visual dysfunction. 
Ophthalmic manifestations are frequent among mitochondrial disorders and can result 
in retinopathy, ocular motility disorders, or optic neuropathy. It is important for 
ophthalmologists to remain cognizant of mitochondrial disease when a patient presents 
with vision loss. Among the mitochondrial diseases, Leber hereditary optic neuropathy 
(LHON) is often considered a prototypical disorder. It was the first mitochondrial 
disease to be recognized by Dr Albrecht von Graefe in 1858, but it was named after 
Dr Theodore Leber who described 15 patients with the disease among four families.1 
LHON was the first disorder recognized to be maternally inherited and the first to be 
attributed to a point mutation in mitochondrial DNA (mtDNA).2,3 Vision loss from 
LHON results from selective degeneration of retinal ganglion cells (RGCs), which are 
highly sensitive to mitochondrial dysfunction and metabolic insult.4 The mechanisms 
involved in the pathogenesis of LHON continue to be elucidated, paving the way for 
research into potential therapeutic interventions.
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Epidemiology
LHON is the most common optic neuropathy caused by a 
primary mutation in mtDNA.5–7 The minimum prevalence of 
vision loss due to the three most common pathogenic point 
mutations in LHON is one in 31,000 in the northern UK.8 
Other epidemiological studies report a prevalence of one in 
39,000 and one in 50,000 in the Netherlands and Finland, 
respectively.9,10 LHON affects predominantly males (in 
80%–90% of cases).5 Symptom onset typically occurs in 
the second and third decades of life. LHON carriers rarely 
lose vision after the age of 50 years, but there have been 
reports of LHON onset from 2 to 87 years of age.5,7,11,12 
Most LHON patients are aware of a family member with 
LHON-compatible vision loss, although 40% deny a known 
family history. Given that de novo mutations are rare, this 
relatively high percentage without a family history could be 
attributable to unrecognized mutation carriers in the family 
who had never lost vision or to the innate difficulty in accu-
rately tracing family history.8,13
Clinical features of vision loss
LHON usually presents as painless, subacute, central visual 
loss in one eye. Weeks to months later, the second eye 
becomes involved, with a median delay of 6–8 weeks.7,14 
Within 1 year, 97% of those affected have involvement of 
the second eye, such that a patient presenting with a unilateral 
optic neuropathy for longer than 1 year is highly unlikely to 
suffer from LHON-related vision loss.5,12,15 Approximately 
25% have bilateral simultaneous vision loss, but in some 
individuals it may be that vision loss in the first eye is not 
noticed before the second eye becomes involved.5,12,14
The majority of individuals progress to a visual acuity 
of 20/200 or worse.16 Due to preferential involvement of the 
papillomacular bundle, the earliest visual field abnormality 
is a cecocentral scotoma (Figure 1), which can enlarge to 
become a larger central defect.16 Dyschromatopsia is common 
and usually parallels the degree of visual acuity loss.5,12,16 
Pupillary light reflexes usually remain intact due to relative 
sparing of melanopsin-containing RGCs. This subset of 
RGCs are thought to be more resistant to metabolic insult 
from mitochondrial dysfunction when compared with all 
RGCs.4,17,18 In cases of asymmetric bilateral or monocular 
vision loss, however, a relative afferent pupillary defect 
can occur.19
On fundus examination preceding or during the acute 
stage of vision loss, there can be characteristic findings, 
including optic disc hyperemia, peripapillary telangiectatic 
blood vessels, vascular tortuosity, and swelling of the retinal 
nerve fiber layer (RNFL) around the optic disc (Figure 2A) 
without corresponding leakage on fluorescein angiography 
(sometimes termed “pseudoedema”). The fundus can look 
normal in 20%–40% of those in the active stage of vision 
loss, which can delay diagnosis.12,20,21 Eventually, as the 
disease progresses, disc hyperemia, peripapillary telangi-
ectasias, and pseudoedema resolve. Approximately 6 weeks 
after onset of vision loss, optic disc pallor develops and can 
be accompanied by cupping of the optic disc, reflecting the 
death of RGCs that occurs in the chronic atrophic phase 
(Figure 2B).5,22
Fundus changes seen in LHON can be further characterized 
and quantified through optical coherence tomography. In the 
acute phase, the RNFL thickens first in the temporal and 
inferior quadrants, then the superior and nasal quadrants.23 
This is consistent with early preferential involvement of the 
papillomacular bundle of RGCs. RNFL thickening is related 
to axonal swelling from impaired mitochondrial function 
Figure 1 Automated 30-2 protocol Humphrey visual field study of the right eye 
showing a dense cecocentral scotoma on the grayscale (A) and total deviation map 
(B) in a patient with acute LHON-related vision loss.
Abbreviation: LHON, Leber hereditary optic neuropathy.
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and axonal transport.4 The RNFL then becomes thinned 
during the chronic phase in the months following the onset of 
vision loss.24 Macular thickness may thin before the RNFL, 
suggesting that disease progression could be better monitored 
with both macular thickness and RNFL measurements by 
optical coherence tomography.25
Visual evoked potentials (VEPs) and electroretinograms 
(ERGs) are often abnormal in affected LHON patients, as 
they reflect optic nerve fiber degeneration and RGC loss, 
respectively. In a study of two brothers with LHON who 
had normal VEP latencies and configurations prior to the 
onset of symptoms, earliest abnormalities included pro-
longed VEP latency and abnormal VEP morphology. With 
symptom progression, there was a progressive prolongation 
of VEP latency.26 In a Brazilian family with a strong history 
of LHON, three affected members had increased latencies, 
decreased amplitudes, or absent responses for pattern-
reversal VEP. Two family members also had reduced ERG 
cone responses.27 Another study found that affected LHON 
patients had increased VEP latency and decreased VEP 
amplitude that was associated with a decreased pattern ERG 
N50–N95 amplitude.28 Notably, VEPs were normal in unaf-
fected carriers in these studies. VEPs and ERGs can therefore 
be useful in diagnosing and monitoring disease progression 
in affected patients.
Magnetic resonance images of the brain and orbits are 
usually normal in affected LHON patients.29 There are, how-
ever, reports of patients with non-specific increased signal 
in the retrobulbar optic nerve on T2-weighted fast spin echo 
and short time inversion recovery sequences months after 
vision loss.30,31 Intravenous gadolinium magnetic resonance 
imaging contrast leads to optic nerve enhancement in patho-
logic states in which there is disruption of the blood–brain 
barrier within the optic nerve.32 Patients with LHON have 
rarely demonstrated optic nerve enhancement on post-contrast 
images, suggesting that in some cases there may be an inflam-
matory component to the pathogenesis of LHON.32
Interestingly, unaffected LHON point mutation carriers can 
display subclinical signs of disease on fundus examination, 
including peripapillary microangiopathy, zones of mild 
disc pseudoedema, and telangiectasias.33 Some seemingly 
asymptomatic carriers do exhibit subclinical dyschromatopsia.34 
Among asymptomatic carriers, temporal RNFL thickening 
on optical coherence tomography may be present, further 
highlighting early involvement of the papillomacular bundle 
in subclinical LHON.35 One study that recorded the pattern 
ERG in asymptomatic LHON mutation carriers showed a 
significant decline in N95 amplitude by ~40% from baseline 
over 36 months, suggesting that subclinical RGC loss is 
progressive in unaffected carriers and precedes the onset of 
visual field defects.36 Pattern ERG may therefore be a useful 
tool to monitor subclinical disease progression in LHON 
mutation carriers.
Prognosis
The visual prognosis in LHON is poor. Most individuals 
have permanent vision loss and are legally registered as 
visually impaired.37 Although vision loss is unlikely to 
progress after the active phase of the disease, patients report 
that the acute phase vision loss has a strong negative impact 
Figure 2 Right optic nerve (A) of a patient with acute LHON-related vision loss showing mild hyperemia, blurring of the disc margin, and elevation of the optic nerve head 
from swelling of the peripapillary retinal nerve fiber layer. LHON-related vision loss in the left eye had occurred 6 months prior leading to prominent temporal optic nerve 
pallor (B) from atrophy of the retinal nerve fiber layer.
Abbreviation: LHON, Leber hereditary optic neuropathy.
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on quality of life.37 Spontaneous visual improvement is a 
well described phenomenon in LHON, usually occurring 
within the first year following vision loss. Recovery can also 
occur decades later.5 Recovery typically presents first with 
the appearance of small islands of vision within the central 
defect bilaterally.20,21 Spontaneous visual recovery is more 
common in patients with the 14484 mutation, with a partial 
recovery rate of 37%–58%, while the 11778 mutation has 
the lowest partial recovery rate of 4%.7,8,14,38 Patients with 
the 3460 mutation have an intermediate prognosis, with an 
approximate 20% partial recovery rate.39 Earlier age of onset 
(younger than 20 years), a subacute time course of vision 
loss, and a larger optic disc are all associated with a better 
visual prognosis.24,40,41
Mitochondrial function and 
oxidative phosphorylation
Mitochondria are double-membraned intracellular organelles 
present in nucleated eukaryotic cells that play a vital role in 
energy generation through production of ATP used for cell 
growth and function.42,43 The number of mitochondria present 
in a particular cell type depends on the energy demands of 
the cell. Cells in highly metabolically active tissues, includ-
ing RGCs within the papillomacular bundle, the cardiac 
conduction system, pancreas, kidney, liver, and muscle, have 
high ATP requirements and high numbers of mitochondria. 
Therefore, mitochondrial diseases predominantly affect 
these tissues, as they are most susceptible to disrupted ATP 
production.4,44,45
ATP generation occurs via oxidative phosphorylation 
(OXPHOS) through the mitochondrial respiratory chain. The 
respiratory chain is made of five complexes (I–V) embedded 
in the inner membrane. Complexes I–IV oxidize NADH and 
FADH
2
 generated from glycolysis and beta-oxidation of 
fatty acids. Complex V, also known as ATP synthase, then 
pumps protons into the intermembrane space and generates an 
electrochemical gradient that facilitates phosphorylation of 
ADP to ATP. Several cofactors, including ubiquinone, play 
an important role in shuttling electrons between respiratory 
chain complexes.4,15,45–47
While ATP production is an essential task of mitochondria, 
the organelles also play other vital roles for the cell, includ-
ing detoxification of reactive oxygen species (ROS), iron 
metabolism, fatty acid oxidation, amino acid biosynthesis, 
and regulation of cellular apoptosis.4,48 Although dysfunction 
of the OXPHOS pathway is one of the most important fac-
tors in the pathogenesis of mitochondrial diseases, defects 
of other cofactors or in the cell machinery that assembles 
mitochondrial components can also disrupt the ATP supply 
and increase production of ROS, which can have devastating 
effects on cells.
Mitochondrial genetics
The genetics of the mitochondria reflect the organelle’s 
evolutionary origins; autonomous proto-mitochondrial 
prokaryotic organisms were thought to be phagocytosed 
by larger eukaryotic cells, forming an endosymbiotic rela-
tionship in which the proto-mitochondria supplied ATP 
and detoxified ROS for the eukaryotic cell.48,49 Similar to 
their proposed prokaryotic origin, mitochondria also have 
a genome in the form of circular double-stranded mtDNA. 
Importantly, mitochondria rely heavily on nuclear DNA 
to encode proteins required for mitochondrial function. 
More than 80 subunits required for the OXPHOS system 
are encoded in the nuclear genome and are imported into 
mitochondria.4 Diseases with mutations in the nuclear 
genome often follow Mendelian inheritance (eg, autosomal 
dominant, autosomal recessive, or X-linked inheritance). 
In contrast, those with primary mutations in mtDNA have 
unique patterns of inheritance and penetrance governed by 
the principles of maternal inheritance, heteroplasmy, replica-
tive segregation, and the critical threshold.50
Transmission of the mitochondrial genome occurs from 
a mother to her progeny. There is no paternal contribution, 
as the few mitochondria present in sperm are proteolytically 
destroyed by the zygote.51 Therefore, LHON results when 
a mother carrying the mutation transmits it to her children, 
while fathers cannot transmit the mutation to offspring.
Unlike nuclear DNA, mtDNA replicates continuously 
and independently of the cell cycle in both dividing and 
non-dividing cells. Often there are several thousands of 
mtDNA molecules present, and all copies are identical. This 
is called homoplasmy. However, a mutation can arise in one 
copy of mtDNA, resulting in coexistence of both mutant 
and wild-type mtDNA within a mitochondrion, termed 
heteroplasmy.45 The principle of heteroplasmy is critical 
when host cells divide and the mitochondria are separated 
between daughter cells. This process is termed replica-
tive segregation and occurs stochastically. The proportion 
of mutant and wild-type mtDNA between daughter cells 
is subject to random segregation and therefore unequal. 
Heteroplasmy and replicative segregation contribute to the 
heterogeneity of mitochondrial disease phenotypes, even 
among related individuals.
In the case of heteroplasmy, a certain amount of wild-type 
mtDNA can compensate for the mutant mtDNA in a cell 
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or tissue. If the effects of the mutant mtDNA exceed a 
certain threshold, however, the wild-type mtDNA can no 
longer compensate. This critical threshold level is often 
tissue-specific; metabolically active tissues, particularly 
the RGCs, which constitute the optic nerve and the cells of 
the retinal pigment epithelium, have a lower threshold than 
less metabolically active tissues.52 In addition, post-mitotic 
cells like neurons accumulate more mutant mtDNA copies 
over time, which eventually exceed the critical threshold 
and account for the age-dependent expression of many 
mitochondrial diseases.44
Over 200 point mutations in mtDNA account for 
mitochondrial diseases. Most point mutations that cause 
disease are heteroplasmic. However, there are several excep-
tions, including the common mutations in LHON, which 
are usually homoplasmic. Deletions and duplications in 
mtDNA can also lead to mitochondrial diseases including 
mitochondrial myopathies, which are often sporadic.15,45,53
Genetics and incomplete penetrance 
of LHON
Ninety percent of all cases of LHON are due to one of 
three  point mutations in mtDNA, which are located at 
nucleotide positions 3460, 11778, and 14484.5 The most 
common point mutation is 11778, which accounts for 70% of 
all cases.5 The 14484 and 3460 mutations account for ~14% 
and ~13%, respectively.20,50 An exception is among those 
of French Canadian descent, in which the 14484 mutation 
accounts for about 90% of cases within that population due 
to a founder effect.54 Other relatively rare mutations have also 
been discovered but occur in single families.20,21 All of the 
mutations occur in genes encoding subunits for complex I 
in the respiratory chain, particularly in those encoding the 
ND1 and ND6 subunits.55,56
LHON is notable for incomplete penetrance, meaning 
that not all mutation carriers will develop vision loss. While 
the mechanisms involved have not been fully elucidated, 
it appears that complex genetic and environmental factors 
play a role.
Like several other mitochondrial disorders, heteroplasmy 
is thought to influence the penetrance of LHON. For 
instance, it has been observed that offspring born to mothers 
with less than 80% mutated mtDNA present in their blood 
are less likely to be symptomatic than offspring born to 
homoplasmic mothers.57 Even more variability is present 
because tissue-specific segregation of mutant mtDNA is 
stochastic during embryogenesis. Considering that 80%–90% 
of all LHON individuals carry homoplasmic mutations, 
heteroplasmy alone does not explain the incomplete 
penetrance of LHON.8,14
Another risk factor for vision loss is the set of inherited 
genes that commonly segregate with the pathogenic mtDNA 
mutation. Over the course of evolution, mtDNA polymor-
phisms have clustered together in groups called haplogroups, 
which tend to be inherited together. The other polymorphisms 
present within a haplogroup can have deleterious effects on 
the OXPHOS pathway, including decreased levels of protein 
synthesis and ATP production, which could then synergize 
with the deleterious effect of the primary LHON mutation.58,59 
For instance, among Caucasians, haplogroup J is associated 
with increased penetrance for the 11778 and 14484 mutation 
carriers, while haplogroup K is associated with increased 
penetrance for the 3460 mutation carriers.60 Chinese carriers 
of the 11778 mutation had an increased risk of vision loss 
when inherited with haplogroup M7b1′2 and a decreased risk 
with haplogroup M8a.61
Differences in mitochondrial mass have also been 
postulated to play a role in the incomplete penetrance of 
LHON. Unaffected LHON mutation carriers have sig-
nificantly higher mtDNA copy numbers in leukocytes than 
affected mutation carriers. Comparison of fibroblasts from 
unaffected, affected, and control patients has shown that cells 
from unaffected carriers have increases in mitochondrial 
transcripts, respiratory chain proteins, enzyme activity, and 
mitochondrial biogenesis factors relative to controls and 
affected carriers. Higher levels of mtDNA in leukocytes in 
unaffected carriers were also associated with milder signs 
of ocular pathology. Thus, mitochondrial mass increases in 
unaffected carriers may be protective, whereby the increased 
amount of mitochondria can compensate for complex I dys-
function. Although the specific factors that activate mitochon-
drial biogenesis remains to be discovered, these observations 
could have implications for the treatment of LHON.62
LHON is maternally inherited. Men cannot transmit the 
mutation. Both male and female offspring can, however, 
inherit the mutation, yet 50% of males and only 10% of 
females experience vision loss; this sex predilection can-
not be explained solely by the principles of mitochondrial 
inheritance.7 It has been hypothesized that there is a reces-
sive X-linked susceptibility gene that works in concert with 
the mitochondrial mutation, which could explain the male 
predominance among carriers who lose vision. Those female 
carriers who do lose vision may either have homozygosity at 
the X-linked locus or may have experienced an unfortunate 
X chromosome inactivation.63 Recent linkage analyses have 
discovered a region on the long arm of the X chromosome 
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that may contain the susceptibility gene, but the actual 
gene responsible has not yet been identified.64–66
Hormonal differences between males and females have 
also been hypothesized to influence the male predomi-
nance in LHON. In females, estrogens are thought to modify 
the severity of mitochondrial dysfunction, including defective 
ATP synthesis, oxidative stress, and apoptosis. In cybrid cell 
lines containing homoplasmic LHON mutations, addition of 
17β-estradiol led to activation of mitochondrial biogenesis, 
increased superoxide dismutase 2 (SOD2) activity, decreased 
production of ROS, and reduction of apoptosis. Estrogen 
receptor β was also shown to be particularly abundant in 
RGCs and their axons within the RNFL.67 The data obtained 
from the cybrid cell model may approximate the effects of 
estrogen on the in vivo target tissue affected in LHON.
Environmental factors have been implicated as contributing 
to vision loss in LHON mutation carriers. Alcohol consump-
tion and tobacco smoking have been associated with the onset 
of vision loss in those genetically predisposed to LHON. 
A retrospective study of 125 European LHON pedigrees 
showed an association between smoking and vision loss, in 
which heavy smokers were more likely to experience vision 
loss than light smokers.68 The study showed a 93% penetrance 
of vision loss in male smokers versus a 66% penetrance 
in male non-smokers. Cigarette smoke can compromise 
complex I activity, reduce cytochrome c oxidase activity, 
and increase production of ROS. Heavy alcohol intake was 
also associated with a greater likelihood of vision loss, but 
this relationship was less significant than that of smoking. 
Other associated environmental triggers include head trauma, 
industrial toxins, and drugs that have mitochondrial toxicity, 
such as antiretrovirals and ethambutol.20 Nutritional deficien-
cies have also been implicated as a trigger for vision loss in 
LHON carriers, including low vitamin B12 levels.69
Optic nerve vulnerability
In LHON, RGCs appear to be selectively vulnerable to 
mitochondrial dysfunction. The papillomacular bundle of 
RGCs responsible for central vision is affected first and 
more severely because of its small-diameter fibers and 
heavy dependence on mitochondria.70 Studies of RGC axons 
show mitochondrial clustering in the prelaminar nerve fiber 
layer, and mitochondria significantly decrease in number 
posterior to the lamina cribrosa where the axons are myeli-
nated. Such an uneven distribution of mitochondria partly 
explains why the unmyelinated portion of RGC axons is 
particularly affected.71–73 It is unclear whether the precipita-
tion of RGC loss is due to low ATP production, increased 
production of ROS, or both, and there are data that support 
both mechanisms.74 A mouse mtDNA mutant model was 
developed that expressed key features of LHON, including 
degeneration of the papillomacular bundle, axonal swelling, 
and dysmorphic mitochondria in unmyelinated segments. 
There was no reduction in ATP synthesis, but there was 
increased ROS production; this research suggests that oxida-
tive stress plays a larger role in the pathogenesis of LHON 
than defective ATP production.75
Of note, optic neuropathy can occur in other mitochon-
drial disorders that have prominent systemic manifestations, 
such as myoclonic epilepsy with ragged red fibers, mitochon-
drial encephalomyopathy, lactic acidosis, and stroke-like 
episodes (MELAS), Leigh syndrome, Friedreich ataxia, 
Mohr–Tranebjerg syndrome, and complicated hereditary 
spastic paraplegia. It remains unclear why mitochondrial 
mutations in other disorders lead to a phenotype with sys-
temic disease. With time, it has become more apparent that 
LHON can be associated with other non-visual neurologic 
sequelae.76
LHON plus
While the typical manifestation of LHON is vision loss, 
there have been other manifestations reported within select 
pedigrees. Cardiac arrhythmias, peripheral neuropathies, 
dystonia, and myoclonus can occur in LHON carriers.20 Some 
families from Holland, Australia, and North America have 
particularly severe manifestations, including ataxia, juve-
nile onset encephalopathy, spastic dystonia, and psychiatric 
disturbances. These phenotypes have been called “LHON 
plus syndromes” and have been linked to other mtDNA point 
mutations that affect OXPHOS complex I activity but differ 
from the three commonly seen in LHON.20,77,78
An association between the 11778 mutation in LHON and 
a demyelinating syndrome that is radiologically and clinically 
identical to multiple sclerosis was described in 1992 and 
named Harding syndrome after the reporting author.79 This 
posed an interesting hypothesis that vision loss in LHON 
may be caused by an abnormal immune response against the 
optic nerve because of mtDNA mutations. In females with 
the 11778 mutation, this immune response may involve other 
myelinated axons and result in a disorder indistinguishable 
from multiple sclerosis. It also poses the question of whether 
mitochondrial genes contribute to susceptibility to multiple 
sclerosis. Some report that the co-occurrence of LHON 
mutations and multiple sclerosis is likely due to chance and 
note that those patients present with atypical symptoms of 
LHON, in which there is a higher female predominance and 
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persisting unilateral vision loss.80 Others report a risk 50 times 
greater than expected for developing both multiple sclerosis 
and LHON, but given the rarity of the syndrome, much more 
remains to be elucidated.81
Treatment
Symptomatic and supportive treatments
The treatment of mitochondrial disorders is still in its infancy. 
Even though there is promising research underway, the 
mainstay of clinical treatment for LHON remains supportive 
rather than curative. Low vision aids can be of substantial 
benefit for those with central vision loss from LHON.82 In 
addition, low vision rehabilitation is a viable option because 
most LHON patients are young adults with intact peripheral 
vision. Patients should also be counselled to optimize envi-
ronmental risk factors for vision loss by avoiding tobacco 
use, heavy alcohol consumption, medications with mito-
chondrial toxicity, and exposure to environmental toxins.20,68 
Other supportive measures, particularly for the LHON plus 
syndromes, includes screening for extraocular manifesta-
tions of LHON, such as a screening electrocardiogram and 
neurological surveillance.83
Nutritional supplements
Several combinations of vitamins (eg, B2, B3, B12, C, E, 
and folic acid) and other supplements such as alpha-lipoic 
acid, carnitine, creatine, L-arginine, and dichloroacetate have 
been tried to treat mitochondrial disorders, including LHON. 
However, analyses have shown little proof of efficacy with 
these interventions.83,84 The rarity of mitochondrial disorders 
makes it particularly challenging to determine efficacy. One 
review noted that only 35 of 1,039 publications had trials 
with more than five patients.85
Brimonidine
Brimonidine is a topical α2-agonist that is used to manage 
patients with glaucoma. Brimonidine has been shown to be 
antiapoptotic, and it can protect RGCs from oxidative damage 
in animal models.86 Nine patients with monocular vision loss 
were treated with topical brimonidine in an open-label trial to 
prevent vision loss in the other eye. However, the study was 
stopped prematurely because all of the patients experienced 
vision loss in their second eye, and brimonidine did not appear 
to mitigate the amount of vision loss.87 Nonetheless, there 
are reports of patients who had both glaucoma and LHON 
in which vision loss was accelerated or worse than expected 
with either disorder alone. It has been proposed that increased 
intraocular pressure may further exacerbate axoplasmic stasis 
in RGCs already under high metabolic stress.88 Brimonidine 
could therefore be potentially useful in asymptomatic LHON 
carriers with glaucoma due to its pressure-lowering effects 
and putative neuroprotective effects.
Ubiquinone analogs
Ubiquinone is a molecule in the mitochondrial membrane 
that carries electrons from complexes I and II to complex III. 
LHON mtDNA mutations affect complex I, so the ubiquinone 
analog coenzyme Q10 is thought to help facilitate the flow of 
electrons and maximize the electrons shuttled to complex III. 
It has long been used in attempts to treat mitochondrial 
disorders, yet recent analyses have not shown significant 
benefit.83–85 Given that coenzyme Q10 is highly lipophilic, 
it is unlikely that oral administration allows for delivery to 
mitochondria.
Idebenone and EPI-743 are short-chain ubiquinone 
analogs that easily enter the brain and reach mitochondria, 
unlike coenzyme Q10. Idebenone has been shown to bypass 
complex I and maintain ATP production, and it inhibits 
lipid peroxidation to protect mitochondria from oxidative 
damage.89,90 Idebenone was initially successful in 1992 with 
a 10-year-old boy who had the 11778 mutation, but this is 
confounded by the fact that childhood-onset LHON has 
higher rates of spontaneous recovery.40,91 A randomized, 
double-blind, placebo-controlled trial called RHODOS 
(Rescue of Hereditary Optic Disease Outpatient Study) 
enrolled 85 LHON patients who had a disease duration of 
up to 5 years. After 24 weeks of idebenone 900 mg/day, the 
study did not show any benefit for the primary outcome of 
best recovery of visual acuity after 24 weeks. However, the 
data showed a positive trend for the secondary end points, 
including change from baseline in best visual acuity and 
change in visual acuity for both eyes, particularly for patients 
with discordant visual acuities.92 The study also found the 
largest treatment effect for patients with the 11778 or 3460 
mutation, while those with the 14484 mutation had a high 
spontaneous recovery rate in the placebo group, thought to 
abolish any treatment effect. In the observational follow-up 
study (RHODOS-OFU), 59 of the original patients were 
followed up 30 months later, and those who were treated 
with idebenone still showed beneficial effects, especially 
those who had a short disease history.93 In a retrospective 
study of 103 LHON patients, 44 patients with disease onset 
within one year were treated with idebenone and followed 
for 5 years or more. Those treated with idebenone recovered 
vision more than the control cohort, and the improvement 
was more prominent with early initiation of treatment and 
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longer duration of treatment.94 Another randomized, double-
blind, placebo-controlled trial of 39 LHON patients with a 
disease duration of less than 5 years treated patients with 
idebenone 900 mg/day for 24 weeks. The treatment group 
showed improvement in blue-yellow color vision and less 
impairment of red-green color vision, and this effect was 
more prominent in those younger than 30 years of age and 
with less than 1 year of symptoms.95 These trials show prom-
ise, but more research is needed to determine the optimal 
idebenone dose and treatment duration, as well as whether 
asymptomatic carriers and those with long disease duration 
can be treated. While not as widely studied as idebenone, 
EPI-743 was used in a trial including five patients with a 
disease duration of 90 days, and four of the five patients 
showed disease arrest and reversal after treatment for a 
minimum of 1 year.96
Pharmacologic activators of 
mitochondrial biogenesis
As noted previously, increased mitochondrial biogenesis 
is significantly associated with unaffected LHON mutation 
carriers and may have a protective effect.62 Mitochon-
drial biogenesis is partly regulated by the transcriptional 
activator PGC-1α, which is controlled by peroxisome 
proliferator-activated receptors and AMP-activated pro-
tein kinase.97 Pharmacologic activators of these proteins 
include fibrates, rosiglitazone, metformin, and AICAR 
(5-aminoimidazole-4-carboxamide ribonucleoside).98 In a 
mouse model of mitochondrial myopathy treated with bezafi-
brate, there was increased mitochondrial biogenesis, a delay 
in onset of the myopathy, and a longer life span.99 However, 
it remains to be seen whether pharmaceutical activation of 
PGC-1α will be beneficial for affected LHON patients or 
mutation carriers.
Gene therapy
Gene therapy has shown some promise for mitochondrial 
diseases. For LHON in particular, it is an even more appeal-
ing treatment option because the RGC layer in the retina 
can be easily accessed. However, the ability to introduce 
genes directly into the mitochondrial genome has not been 
well developed, and a large obstacle is the double mem-
brane of the mitochondrion. Thus, researchers have utilized 
allotopic expression by transfecting the desired gene into 
the nuclear genome instead.100–102 For this technique, the 
desired wild-type gene is engineered with a mitochondria-
specific targeting sequence so that the wild-type protein 
product is imported into the mitochondria. The gene is 
then transfected into the nucleus with an adeno-associated 
virus (AAV) vector. One of the first successful attempts in 
vitro was on a cybrid cell line that was homoplasmic for 
the 11778 mutation, in which researchers used allotopic 
expression to complement the mutated ND4 subunit with 
a wild-type one, and rescued ATP synthesis.103 Two animal 
models expressing the mutated ND4 subunit also showed 
an improvement in vision and rescue of RGCs following 
intravitreal injection and allotopic expression of the wild-
type gene for ND4.104,105 However, limitations remain due 
to inefficient mitochondrial import of the hydrophobic 
ND4 subunit, and allotopic expression can be optimized 
by targeting the mRNAs to the mitochondrial surface to 
couple translation and translocation for a longer duration 
of gene expression.106 Clinical trials associated with the 
University of Miami, Huazhong University of Science and 
Technology, and Gensight Biologics are currently recruit-
ing patients with the 11778 mutation to assess the safety of 
gene therapy with an AAV vector carrying the wild-type 
ND4 gene.107–109
Another gene that has been allotopically expressed in 
cells harboring the 11778 mutation is the SOD2 gene, which 
detoxifies free radicals in mitochondria. Even though the 
SOD2 gene is encoded in the nuclear genome and expressed 
in LHON carriers, SOD2 activity is attenuated in cells 
homoplasmic for an LHON mutation.110 In LHON cybrids, 
overexpression of SOD2 through transfection with an AAV 
vector led to a decreased rate of apoptosis, which highlights 
how antioxidant mechanisms could improve RGC survival 
in LHON.111
More recent approaches have shown that it is possible 
to introduce genes into mitochondria, although it remains 
technically difficult. One study isolated whole mtDNA 
from healthy human donors and developed a construct with 
recombinant mitochondrial transcription factor A protein 
that could gain direct entry into mitochondria. This construct 
was then applied to LHON cybrids that were homoplasmic 
for the 11778 mutation, and it stimulated mitochondrial 
biogenesis.112 Another study used a mitochondrial targeting 
sequence on the AAV vector capsid that contained the wild-
type ND4 gene. The mitochondrial targeting sequence led 
to direct introduction of the wild-type ND4 gene into mito-
chondria in vitro and in a mouse model, in which there was 
restoration of ATP synthesis.113 The same researchers then 
discovered that the mitochondrial targeting sequence-guided 
gene construct did not recombine with the host mitochondrial 
genes but rather remained episomal in the mitochondria.114 
This discovery is encouraging, as it appears unlikely that the 
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gene construct recombines with endogenous genes, which 
could further disrupt the OXPHOS pathway. These studies 
show immense therapeutic potential, but research remains 
preliminary and further studies are required to evaluate 
adverse effects and determine how long the beneficial effects 
would last.
Stem cells
The use of stem cells to treat mitochondrial optic 
neuropathies is still in the preliminary stages, but two tech-
niques are currently under investigation. One technique 
involves transplantation of RGCs. However, harvesting 
mature and fully functioning RGCs from embryonic stem 
cells or induced pluripotent stem cells remains challenging, 
and is further compounded by the difficulty in ensuring that 
transplanted RGCs make the correct neuronal connections 
when integrated into the retina.115 For now, it appears that 
mature RGCs derived from stem cells can be used for fur-
ther in vitro research of LHON pathogenesis and potential 
treatments.
Also under current investigation is the use of stem cells 
to provide neurotrophic factors that protect RGCs.116 Because 
some patients with LHON experience visual recovery, 
they have some RGCs that survive despite mitochondrial 
dysfunction and oxidative stress. To protect these surviving 
RGCs, use of mesenchymal stem cells that secrete neu-
rotrophic factors and anti-inflammatory cytokines appears 
promising. Intravitreal injection of autologous mesenchymal 
stem cells in a rat model with glaucoma showed a neuropro-
tective effect with increased RGC axon survival.117 Another 
study used intravenous infusions of autologous bone-marrow 
derived mesenchymal stem cells in ten patients with sec-
ondary progressive multiple sclerosis, who experienced 
an improvement in visual acuity and an increase in optic 
nerve area without significant adverse effects.118 Given this 
proof-of-concept study, the same strategy could be employed 
in the future to slow the loss of RGCs in LHON. Patients 
should be cautioned that lucrative, unregulated stem cell 
treatments offered at clinics not affiliated with academic 
research centers may make inflated promises of efficacy and 
could be dangerous.
Conclusion
LHON remains the prototype mitochondrial optic neuropa-
thy and is marked by acute onset of sequential bilateral 
optic neuropathy due to point mutations in mtDNA. Symp-
tom onset typically begins in the second or third decade of 
life as a painless and subacute monocular loss of central 
vision that then progresses to involve the other eye. While 
partial visual recovery may occur, most patients remain 
legally blind and require low vision services. Optic nerve 
degeneration results from dysfunctional OXPHOS and 
increased production of ROS within mitochondria, and 
RGCs within the papillomacular bundle serving central 
vision are particularly susceptible to oxidative stress. 
The LHON inheritance pattern follows that of mitochon-
drial genetics and is maternally inherited. Incomplete 
penetrance occurs as a result of both genetic and envi-
ronmental factors, leading to wide symptom variability 
among mutation carriers.
Although research for LHON is ongoing and new 
discoveries are continuously made, many questions remain 
to be answered before a curative treatment becomes first-line 
therapy for patients with this debilitating disease. In vitro cell 
studies and animal models have shown promise, and now 
the field is progressing to early phase clinical trials. At this 
point, however, the efficacy, adverse effects, and duration 
of treatment benefit have yet to be determined.
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